52-Week Performance Chart

From time to time, BNY may pay a rebate to brokers that deposit shares with BNY for the issuance of unsponsored depositary receipts (DRs) or global depositary notes. BNY assumes no obligation or responsibility, and expressly disclaims any liability arising out of, or relating to, such rebates, including without limitation whether the rebate or any portion of it is passed on to the beneficial holders by the brokers.
Unsponsored DRs may be issued by multiple depositary banks servicing a particular DR program. Consequently, as a result of Depository Trust & Clearing Corporation (“DTCC”) practice, the actual cash distribution fees charged may differ from the BNY fees detailed in the fee schedule as fees will be charged in accordance with the fee schedule of the depositary bank that is considered to be the “First Filer”. The fees to be charged for any particular unsponsored cash distribution will be disclosed on the event announcement published by the “First Filer”. BNY takes no responsibility for the level of fees charged by any other depositary bank. The “First Filer” is the depositary bank that filed the first Form F-6 for a program with the U.S. Securities and Exchange Commission (“SEC”). In the event the actual “First Filer” does not have DRs outstanding for a program, the next depositary bank who filed a
Form F-6 with the SEC and has DRs outstanding will be deemed to be the First Filer for these purposes.

DR Details

DR Symbol	SBHMY
CUSIP	82937X103
DR Venue	OTC
DR ISIN	US82937X1037
Ratio DR:ORD	1:20
First Filer	DB
Underlying ISIN	KYG8167W1380
Underlying SEDOL	B00XSF9
Country	Hong Kong
Effective Date	May 21, 2014
Depositary	BK, CIT, DB, JPMC (Unsponsored)
Industry	Pharma. & Biotech.

Sino Biopharmaceutical is a research and development (R&D) driven pharmaceutical conglomerate in the People's Republic of China. The Company's business encompasses a fully integrated chain in pharmaceutical products which covers an array of R&D platforms, a line-up of intelligent production and a sales system. The Company's products are present in various therapeutic categories, comprising a variety of biopharmaceutical and chemical medicines for treating tumours, liver disease, cardio-cerebral diseases, analgesia, respiratory system diseases and orthopaedic diseases. The Company also actively establishes and extends co-operations with domestic and overseas pharmaceutical institutes and enterprises.

Data provided by Mergent, Inc.

Fee Type in US Dollar per ADS	Deposit Agreement
Annual Depositary Service	up to $0.1000
Cancellation	up to $0.1000
Cash Distribution	up to $0.1000
Issuance	up to $0.1000
Registrar Inspection	up to $0.0000
Cash Distribution(Other)	up to $0.1000
Rights - Issuance	up to $0.1000
Stock Dividend	up to $0.1000
Transfer	up to $0.0000
Cable Fee per Cancellation	$17.5000

Monthly Trading Summary

Month	Month End DR Close Price	DR Trading Volume	Avg Day DR Trading Volume
Apr.25	10.08	1,785	137
Mar.25	9.64	3,199	533
Feb.25	8.28	319	53

Depositary Receipts Foreign Exchange Pricing Disclosure

Sino Biopharmaceutical Limited Homepage

Hong Kong and Shanghai Banking Corp. (HK)/HSBCHKHHSEC